FRANKFURT, Germany (AP) — Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.
Business - Boston.com, Boston Globe: Business
Thu, 03/07/2013 - 1:17am
FRANKFURT, Germany (AP) — Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.